Advances in antisense efficacy and delivery.
Agrawal
S
S
Pharmaceutical Sciences Institute, Aston University, Birmingham, UK.
Akhtar
S
S
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use; D001692:Biological Transport; D002986:Clinical Trials as Topic; D003586:Cytomegalovirus Infections / Q000188:drug therapy; D004337:Drug Carriers; D015195:Drug Design; D015497:HIV-1 / Q000235:genetics; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000235:genetics; D008081:Liposomes; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage* / Q000378:metabolism / Q000627:therapeutic use*; D027383:Papillomaviridae; D030361:Papillomavirus Infections / Q000188:drug therapy; D013873:Thionucleotides; D014412:Tumor Virus Infections / Q000188:drug therapy
D000998:Antiviral Agents; D004337:Drug Carriers; D008081:Liposomes; D016376:Oligonucleotides, Antisense; D013873:Thionucleotides; D018799:Intercellular Adhesion Molecule-1